MODEL VERDICT
Inovio Pharmaceuticals, Inc. (INO) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 182 industry peers | $2.05 | +21.3% | 4% | B | Data |
| Price / Sales 184 industry peers | $0.06 | -96.4% | 3% | B | Model Driven |
| Weighted Output Blended model output | $3.19 | +88.9% | 100% | 52 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 23.19 | 17.51 | 0.73 | 61.90 | 25.85 |
| P/B Ratio | 148.42 | 32.16 | 0.73 | 913.07 | 337.81 |
| P/S Ratio | 1635.57 | 228.26 | 36.27 | 7241.33 | 2619.73 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates INO's fair value at $3.19 vs the current price of $1.69, implying +88.9% upside potential. Model verdict: Significantly Undervalued. Confidence: 52/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $3.19 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%).
INO's current P/E of -0.4x compares to the industry median of 23.5x (45 peers in the group). This represents a -101.8% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
17 analysts cover INO with a consensus rating of Buy. The consensus price target is $6.00 (range: $6.00 — $6.00), implying +255.0% upside from the current price. Grade breakdown: Strong Buy (0), Buy (9), Hold (6), Sell (2), Strong Sell (0).
The model confidence score is 52/100, based on: data completeness (0), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for INO.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.